health
Drugmakers race to find a place in the next wave of obesity drugs
Drugmakers are betting they can crack into the obesity drug market that Novo Nordisk and Eli Lilly currently dominate.
TL;DR
- Drugmakers are developing new obesity drugs with less frequent dosing and potentially fewer side effects.
- Oral GLP-1 pills are entering the market, aiming to increase accessibility to weight-loss treatments.
- New companies are emerging with innovative drugs beyond GLP-1s, targeting areas like amylin.
- Eli Lilly's experimental triple-acting drug retatrutide has shown unprecedented weight loss results.
- The competition is increasing, with investors assessing market dynamics beyond the current duopoly of Eli Lilly and Novo Nordisk.
- Pricing and insurance coverage remain critical factors for market access and patient adoption.